Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients

Acta Biochimica et Biophysica Sinica

Volumn 42, Issue 5, 2010, Pages 311-317

  Cheng, Hongyan ^a   Sun, Ning ^b   Sun, Xinchen ^c   Chen, Baoan ^a   Li, Fan ^a   Feng, Jifeng ^b   Cheng, Lu ^a   Cao, Yuandong ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Gene chip microarray; Non small cell lung cancer (NSCLC); Single nucleotide polymorphism (SNP)

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PLATINUM; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; AGED; ARTICLE; ASIAN; CANCER STAGING; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NUCLEAR PROTEINS; PLATINUM; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77951798499     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmq023     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007, 57: 43-66.
2. Hoffman PC, Mauer AM and Vokes EE. Lung cancer. Lancet 2000, 355: 479-485.
3. Bunn PA and Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998, 4: 1087-1100.
4. Rosell R, Cecere F, Santarpia M, Noemi R and Miquel T. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006, 6: 323-331.
5. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andrée F, Haddad V and Taranchon E, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Eng J Med 2006, 355: 983-991.
6. Jordan P and Carmo-Fonseca M. Molecular mechanisms involved in cis-platin cytotoxicity. Cell Mol Life Sci 2000, 57: 1229-1235.
7. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H and Begg AC. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000, 89: 160-166.
8. Hsieh P. Molecular mechanisms of DNA mismatch repair. Mutat Res 2001, 486: 71-87.
9. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 1996, 93: 6443-6447.
10. Mello JA, Acharya S, Fishel R and Essigmann JM. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 1996, 3: 579-589.
11. Fink D, Aebi S and Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998, 4: 1-6.
12. Zdraveski ZZ, Mello JA, Farinelli CK, Essigmann JM and Marinus MG. MutS preferentially recognizes cisplatin over oxaliplatin-modified DNA. J Biol Chem 2002, 277: 1255-1260.
13. Branch P, Aquilina G, Bignami M and Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993, 362: 652-654.
14. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC and Hamilton TC, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998, 58: 3579-3585.
15. Brown R, Hirst GL, Gallagher WM, Amanda J, Geoffrey P and Ate GJ. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997, 15: 45-52.
16. Drummond JT, Anthoney A and Brown R. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996, 271: 19645-19648.
17. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22: 7265-7279.
18. Worrillow LJ, Travis LB, Smith AG, Sara R, Andrew JS and Christopher PW. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003, 9: 3012-3020.
19. Paz-y-Mińo C, Pérez JC, Fiallo BF and Leone PE. Polymorphism in the hMSH2 gene (gIVS12-6T>C) associated with non-Hodgkin lymphomas. Cancer Genet Cytogenet 2002, 133: 29-33.
20. Palicio M, Blanco I, Tórtola S, González I, Marcuello E, Brunet J and Liuis F, et al. Intron splice acceptor site polymorphism in the hMSH2 gene in sporadic and familial colorectal cancer. Br J Cancer 2000, 82: 535-537.
21. Goessl C, Plaschke J, Pistorius S, Hahn M, Frank S and Hampl M. An intronic germline transition in the HNPCC gene hMSH2 is associated with sporadic colorectal cancer. Eur J Cancer 1997, 33: 1869-1874.
22. Brentnall TA, Rubin CE, Crispin DAAS, Robert HB and Rodger CH. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 1995, 109: 151-155.
23. Jung CY, Choi JE, Park JM, Chae MH, Kang HG, Kim KM and Lee SJ, et al. Polymorphisms in the hMSH2 gene and the risk of primary lung cancer. Cancer Epidem Biomar 2006, 15: 762-768.
24. Frederick LG, April GF, Charles MB, Daniel GH, David LP, Irvin DF and Morrow M. AJCC Cancer Staging Handbook, 6th edn. New York: Springer, 2002.
25. Miller AB, Hoogstraten B and Staquet M. Reporting results of cancer treatment. Cancer 1981, 47: 207-214.
26. Xiao PF, Cheng L, Wan Y, Sun BL, Chen ZZ, Zhang SY and Zhang CZ, et al. An improved gel-based DNA microarray method for detecting single nucleotide mismatch. Electrophoresis 2006, 27: 3904-39015.
27. Chen HY, Yu SL, Chen CH, Chang GC and Chen CY. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356: 11-20.
28. Feng J, Sun X, Sun N, Qin S, Li F, Cheng H and Chen B, et al. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin 2009, 41: 429-435.
29. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J and Kane M, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75: 1027-1038.
30. Lowsky R, DeCoteau JF, Reitmair AH, Ichinohasama R, Dong WF, Xu Y and Mark TW, et al. Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL). Blood 1997, 89: 2276-2282.
31. Brentnall TA, Rubin CE and Crispin DA. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 1995, 109: 151-155.
32. Xia L, Shen W, Ritacca F, Angela M, Lisa M and Terri B. A truncated hMSH2 transcript occurs as a common variant in the population: implications for genetic diagnosis. Cancer Res 1996, 56: 2289-2292.
33. Bubb VJ, Curtis LJ and Cunningham C. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996, 12: 2641-2649.
34. Hsu HS, Lee IH, Hsu WH, Kao WT and Wang YC. Polymorphism in the hMSH2 gene (gISV12-6T>C) is a prognostic factor in non-small cell lung cancer. Lung Cancer 2007, 58: 123-130.
35. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D and Christen RD, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56: 3087-3090.
36. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A and Christen RD, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996, 56: 4881-4886.
37. Han HJ, Maruyama M, Baba S, Park JG and Nakamura Y. Genomic structure of human mismatch repair gene hMLH1 and its mutation analysis in patients with hereditary non-polyposis colorectal cancer (HNPCC). Hum Mol Genet 1995, 4: 237-242.
38. Nyström-Lahti M, Wu Y, Moisio AL, Hofstra RM, Osinga J, Mecklin JP and Järvinen HJ, et al. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet 1996, 5: 763-769.
39. Benachenhou N, Guiral S, Gorska-Flipot I, Labuda D and Sinnett D. High resolution deletion mapping reveals frequent allelic losses at the DNA mismatch repair loci hMLH1 and hMSH3 in non-small cell lung cancer. Int J Cancer 1998, 77: 173-180.
40. Xiao PF, Huang H, Zhou G and Lu Z. Gel immobilization of acrylamide-modified single-stranded DNA template for pyrosequencing. Electrophoresis 2007, 28: 1903-1912.